Revolutionizing Oncology: Pfizer's PD-1xVEGF Breakthrough - Pharma and BioTech Daily

Episode Overview

Title: Revolutionizing Oncology: Pfizer's PD-1xVEGF Breakthrough
Date: November 13, 2025
Podcast: Pharma and BioTech Daily
Host: Pharma and BioTech News

This episode highlights the transformative developments underway in the pharmaceutical and biotech industries, with a special focus on Pfizer’s pioneering bispecific antibody targeting PD-1 and VEGF pathways in non-small cell lung cancer. The episode contextualizes this innovation within a broader landscape of strategic mergers, regulatory advances, emerging clinical data, and evolving industry trends.

Key Discussion Points & Insights

1. Pfizer’s PD-1xVEGF Bispecific Antibody: Redefining Oncology Treatments

[00:15–01:10]

Announcement of Phase 3 Trials: Pfizer’s PFO8634404, a bispecific antibody for non-small cell lung cancer, enters Phase 3, aiming to "supersede Keytruda by simultaneously targeting the PD-1 and VEGF pathways."
Industry Significance: This approach spotlights the next wave of immunotherapies, aiming for superior efficacy by attacking tumor growth and immune evasion "through this dual targeted strategy."
Broader Commitment: Pfizer is "announcing seven near term trials," emphasizing its dedication to next-generation therapies with potential to "improve patient outcomes and redefine first line therapies."

"Pfizer could set new standards in lung cancer treatment, potentially improving patient outcomes and redefining first line therapies." — Host [00:56]

2. Major Industry Moves & Mergers

[01:10–02:05]

Mallinckrodt & Endo Merge to Form Kinova ($6.7B Transaction):
- The new entity spins off PAR Health generics, instead focusing on rare diseases—"a trend increasingly seen across the industry as companies pivot towards niche markets with high unmet needs."
Implications: Corporate strategies are shifting to specialty pharma, reflecting the pursuit of higher-value treatments in under-served areas.

3. Funding & Investor Confidence

[02:05–02:30]

Vorbio’s $100M Public Offering: Showcases the investment community’s belief in therapies for autoimmune diseases, accelerating "clinical stage programs, potentially transforming patient care in this challenging therapeutic area."

4. Regulatory Milestones & International Expansions

[02:30–03:00]

Glenmark’s Rialtris Wins Approval in China:
- Now available for moderate to severe allergic rhinitis, unlocking the Chinese respiratory therapeutics market with an "innovative small molecule therapy," signaling strategic global expansion.

5. Clinical Trial Highlights

[03:00–03:50]

Cell A Core Therapeutics’ Zelenfaban: Success in phase 3 for myocardial infarction.
Ubavax’s DPV001: Improved survival in head & neck cancer.
Ingene’s Ditalamo Genevoroplasmid: 63% response in bladder cancer patients unresponsive to BCG, all reflecting “ongoing advances in targeted therapies and personalized medicine approaches.”

6. Policy Shifts: Towards Humane Drug Development

[03:50–04:15]

UK’s Five-Year Roadmap:
- Plan to replace animal testing with AI and 3D tissue models.
- Described as “a pivotal shift towards more ethical and technologically advanced methods in drug development,” aligning with global trends for humane practices.

“This initiative marks a pivotal shift towards more ethical and technologically advanced methods in drug development.” — Host [04:04]

7. Regulatory Leadership Changes

[04:15–05:00]

Richard Pasder Appointed FDA CDER Director: Praised for "extensive experience in oncology," expected to “streamline drug approval processes, particularly for oncology drugs,” potentially accelerating patient access to new therapies.

“Pastor’s new role could have broad implications for drug development strategies and patient care.” — Host [04:45]

8. Setbacks, Strategy, and Resilience in R&D

[05:00–06:10]

Novo Nordisk: Mixed Phase 2 results in antibody for transthyretin amyloidosis with cardiomyopathy—demonstrates industry's perseverance amid inevitable R&D setbacks.
Bayer: Faces flat sales but bets on new products (e.g., Linq) and streamlines pipeline by "discontinuing several early stage cancer projects," opting to "prioritize promising candidates."
Metagenomy: Refocuses on hemophilia gene editing, indicative of "financial pressures faced by smaller biotech firms striving for breakthroughs."
Johnson & Johnson/Legend Biotech: Withdraw abstract on CAR T—possible "strategic recalibrations," but "anticipation surrounding CAR T treatments remains high."

9. Evolving Patient Support & Tech Adoption

[06:10–06:45]

Industry conversations increasing about deploying technology and data analytics to enhance patient support, especially for managing complex therapies.

10. Market Dynamics & Consolidation

[06:45–End (~07:20)]

Pfizer Acquires Metsira: Part of a "broader trend within pharma seeking portfolio diversification," underlining the sector’s relentless focus on innovative solutions for changing healthcare demands.

Notable Quotes & Timestamps

On Pfizer's ambition in oncology:

"Pfizer is making substantial strides with its PD-1xVEGF bispecific antibodies by announcing seven near term trials... could set new standards in lung cancer treatment." — Host [00:36 & 00:56]
On industry strategy pivots:

"Such a move indicates a focused shift towards specialty pharmaceuticals aimed at rare diseases, a trend increasingly seen across the industry as companies pivot towards niche markets with high unmet needs." — Host [01:28]
On investor optimism:

"Vorbio's successful $100 million public offering highlights growing investor confidence in companies addressing autoimmune diseases." — Host [02:13]
On regulatory innovation:

"The UK government has unveiled a five year roadmap aimed at replacing animal testing with AI and 3D tissue models." — Host [03:53]
On leadership at the FDA:

"His focus on streamlining drug approval processes, particularly for oncology drugs, could accelerate patient access to innovative therapies." — Host [04:52]

Summary & Takeaways

This episode offers a panoramic view of the pharmaceutical and biotech industry’s rapid evolution, with Pfizer's innovative lung cancer immunotherapy at the vanguard. Listeners are brought up to speed on major corporate deals, promising clinical data, pivotal regulatory milestones, and the embrace of new technologies and patient-centric strategies. The tone remains optimistic yet realistic, emphasizing both the tremendous progress being made and the challenges still faced.

Transcript

A (0:00)

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we delve into a series of compelling updates that underscore the dynamic nature of our industry marked by scientific breakthroughs, strategic shifts, regulatory advancements and more. Starting with Pfizer's ambitious endeavors in oncology, the company has initiated Phase 3 trials for its bispecific antibody PFO8634404 targeting non small cell lung cancer. This innovative approach aims to supersede Keytruda by simultaneously targeting the PD1 and VEGF pathways crucial in tumor growth and immune evasion. Pfizer is making substantial strides with its PD1X VEGF B specific antibodies by announcing seven near term trials, including a pivotal Phase 3 trial comparing this agent to keytruda in non small cell lung cancer. This underscores Pfizer's commitment to developing next generation immunotherapies that could redefine cancer treatment paradigms by offering more targeted the implications are significant. By enhancing therapeutic efficacy through this dual targeted strategy, Pfizer could set new standards in lung cancer treatment, potentially improving patient outcomes and redefining first line therapies. Meanwhile, a strategic merger between Mallinkrodt and Endo has culminated in a $6.7 billion transaction, resulting in the rebranding of the combined entity as Kinova. This merger is particularly notable for its decision to spin off the PAR health generics business. Such a move indicates a focused shift towards specialty pharmaceuticals aimed at rare diseases, a trend increasingly seen across the industry as companies pivot towards niche markets with high unmet needs. In financing news, Vorbio's successful $100 million public offering highlights growing investor confidence in companies addressing autoimmune diseases. This capital will likely accelerate Vorbios clinical stage programs, potentially transforming patient care in this challenging therapeutic area through new and effective treatments. On the regulatory front, Glenmark's Rialtris has secured approval from China's National Medical Products Administration for treating moderate to severe allergic rhinitis. This approval is pivotal as Glenmark expands its footprint in respiratory therapeutics with innovative small molecule therapies designed to alleviate allergy symptoms, a sign of their strategic growth within this domain. Recent clinical trial results also offer promising news. Cell A Core Therapeutics Zelenfaban has shown phase three success for segment elevation myocardial infarction, while Ubavax DPV001 has demonstrated improved survival rates in head and neck squamous cell carcinoma ingenes ditalamo genevoroplasmid exhibited a 63% response rate in bladder cancer patients unresponsive to BCG therapy. These findings reflect ongoing advances in targeted therapies and personalized medicine approaches that continue to reshape the oncology landscape in policy changes. The UK government has unveiled a five year roadmap aimed at replacing animal testing with AI and 3D tissue models. This initiative marks a pivotal shift towards more ethical and technologically advanced methods in drug development, potentially accelerating discovery processes while reducing reliance on animal models, a significant move that aligns with global trends towards more humane scientific practices. Meanwhile, Richard Pasder's appointment as director of the FDA's center for Drug Evaluation and Research signals strategic leadership changes amidst ongoing organizational investigations. His extensive experience in oncology is expected to guide regulatory oversight during this transformative period for the agency. Dr. Richard Pasder's appointment as director of CDER represents another key development. A longtime leader in oncology at the fda, Pastor's new role could have broad implications for drug development strategies and patient care. His focus on streamlining drug approval processes, particularly for oncology drugs, could accelerate patient access to innovative therapies. Novo Nordisk faced mixed phase two results with its antibody treatment for transfyretin amyloidosis with cardiomyopathy. While setbacks like these underscore inherent challenges in developing novel therapies for complex cardiovascular conditions, they also highlight the industry's resilience and commitment to innovation despite hurdles. Overall, these updates reflect an industry dynamically evolving through scientific innovation, strategic mergers, regulatory advancements and policy shifts. The implications for patient care are profound as these developments promise enhanced therapeutic options across various disease areas, underscoring the ever growing importance of precision medicine in targeted therapies in modern healthcare. Bayer faces challenges with stagnating pharmaceutical sales but remains optimistic about its pipeline of newer medications like linq. The company is also addressing misinformation through campaigns, reinforcing public confidence in scientific advancements, and has streamlined its oncology research by discontinuing several early stage cancer projects, a strategic decision reflecting broader industry trends. Prioritizing promising candidates Metagenomy is refocusing on its preclinical hemophilia program amidst significant workforce reductions. This strategic pivot towards gene editing applications highlights financial pressures faced by smaller biotech firms striving for breakthroughs, an area ripe with potential given recent advancements in CRISPR technology. Johnson and Johnson and Legend Biotech have withdrawn an abstract from an upcoming meeting evaluating Carvic T against rival CAR T therapies, a move suggesting potential strategic recalibrations or data reevaluation before further disclosure. Yet anticipation surrounding CAR T treatments remains high due to their transformative potential. The evolution of patient support services continues as discussions on leveraging technology and data analytics gain traction, a crucial factor for managing complex therapy regimens and improving outcomes. These developments reflect both opportunities and challenges within pharma biotech industries, navigating regulatory landscapes, clinical trial complexities, market pressures, and underline an ongoing focus on innovation coupled with strategic adjustments driving forward scientific excellence aimed at advancing patient care. Finally, Pfizer's acquisition of Metsira marks yet another significant transaction within an industry marked by consolidation efforts aimed at enhancing competitive positions while focusing on high potential products across therapeutic areas. A broader trend within pharma seeking portfolio diversification amidst increasing competition among major players pursuing innovative solutions tailored specifically towards evolving healthcare demands worldwide.